Viridian Therapeutics, Inc.
VRDN
$16.86
-$0.34-1.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 23,382.78% | 23,359.93% | 23,340.07% | 5.90% | 4.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23,382.78% | 23,359.93% | 23,340.07% | 5.90% | 4.86% |
| Cost of Revenue | 25.71% | 41.31% | 54.23% | 79.93% | 135.46% |
| Gross Profit | 0.61% | -11.72% | -19.85% | -80.06% | -135.79% |
| SG&A Expenses | 85.07% | 56.04% | -1.61% | -20.81% | -28.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.41% | 46.24% | 40.79% | 48.12% | 41.63% |
| Operating Income | -15.49% | -22.69% | -15.93% | -48.17% | -41.67% |
| Income Before Tax | -16.95% | -26.91% | -17.46% | -50.87% | -41.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.95% | -26.91% | -17.46% | -50.87% | -41.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.95% | -26.91% | -17.46% | -50.87% | -41.35% |
| EBIT | -15.49% | -22.69% | -15.93% | -48.17% | -41.67% |
| EBITDA | -15.53% | -22.76% | -15.99% | -48.31% | -41.79% |
| EPS Basic | 0.39% | -7.62% | -29.53% | -40.24% | -9.67% |
| Normalized Basic EPS | 5.68% | -1.91% | 13.77% | -4.80% | 5.95% |
| EPS Diluted | 0.39% | -7.62% | -29.53% | -40.24% | -9.67% |
| Normalized Diluted EPS | 5.68% | -1.91% | 13.77% | -4.80% | 5.95% |
| Average Basic Shares Outstanding | 23.42% | 24.93% | 34.73% | 41.74% | 47.54% |
| Average Diluted Shares Outstanding | 23.42% | 24.93% | 34.73% | 41.74% | 47.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |